Coagulation Dysfunctions: A Hallmarks for Thrombo-Inflammatory Risks in SARS-CoV-2 Hospitalized Patients

Abstract

The relevance of coagulation malfunction in COVID-19 (severe coronavirus disease) is ambiguous. Current study aimed to assess the coagulation among SARS-CoV-2 hospitalized patients. A cross
sectional study with qualitative approach was conducted among 300 patients who are already diagnosed as
COVID 19 compared to 300 apparently healthy control group attended to Red Sea State during study period
from April 2020 to April 2021. The Humaclot Due Plus1 coagulation analyser was used to estimate the prothrombin time (PT), activated partial prothrombin time (APTT), and international normalized ratio (INR)
(Wiesbaden 1, Germany), adding 25 μL of plasma in cuvette. The study result showed that in COVID-19 patients D.dimer level is high (2000-10000 ng/mL) compared with control group (up to 500 ng/mL). COVID-19
infection cause high D. dimer level which can lead to thrombosis event or bleeding tendency. Abnormal
coagulation results were revealed among SARS-CoV-2, with markedly elevated D. dimer